Policy outcomes
How this issue is resolved shapes the rules voters live under.
The issue in plain English
Should the federal government cap the price of insulin?
After Congress capped insulin copays at $35 a month for Medicare beneficiaries in 2022, debate has continued over whether to extend a similar limit to all patients. Supporters argue a broader cap is needed to ensure affordability and parity with other wealthy nations, while opponents question the role of federal price controls and point to recent voluntary reductions by manufacturers.
Why this matters
What the answer actually changes.
Representation
The arguments reveal who gets a stronger voice when the question is settled.
Trust
Whether the process feels fair influences how voters trust the outcome.
The arguments
Two sides of the debate.
The goal is not to decide for the voter. It is to make the strongest competing views easy to understand.
Supporters say
The case for a federal cap
Supporters argue that insulin is a medically necessary drug for the 8.4 million Americans who rely on it and that high costs have led some patients to ration doses, with documented health consequences. They point to a 2022 RAND study finding U.S. list prices averaged roughly $98 per unit in 2018, compared with $7.52 in the United Kingdom and $12 in Canada, as evidence that market forces alone have not produced affordability comparable to peer nations. Proponents also contend that the Medicare $35 cap demonstrates that a federal limit is workable, and that extending it to privately insured patients would close coverage gaps and reduce reliance on voluntary corporate pricing decisions that could be reversed. They argue a uniform federal standard would simplify the patchwork of state laws and manufacturer programs.
Critics say
The case against a federal cap
Opponents argue that federal price caps amount to government price-setting that could discourage research and investment in next-generation insulin products and biosimilars. They contend that recent voluntary reductions by Eli Lilly, Novo Nordisk and Sanofi — along with new lower-priced biosimilars entering the market — show that competition and public pressure can lower prices without direct federal mandates. Critics also question whether a cap addresses the underlying drivers of high list prices, including rebate arrangements among manufacturers, pharmacy benefit managers and insurers. Some warn that mandating lower out-of-pocket costs could shift expenses to premiums or to taxpayers, and that broader insurance-design reforms or transparency measures may be more effective than a federal price ceiling.
Key facts
Numbers behind the question.
$35
Monthly insulin copay cap for Medicare Part D beneficiaries under the 2022 Inflation Reduction Act
Public Law 117-169
8.4 million
Americans who use insulin to manage diabetes
Centers for Disease Control and Prevention
$98 vs. $7.52
Average U.S. insulin list price per unit in 2018, compared with the United Kingdom
RAND Corporation, 2022
3
Major manufacturers — Eli Lilly, Novo Nordisk and Sanofi — that announced voluntary price reductions in 2023
Company announcements
Context
How the debate took shape
Insulin has been used to treat diabetes for more than a century, but U.S. list prices rose sharply in the 2000s and 2010s, drawing congressional scrutiny and state-level action. The Inflation Reduction Act of 2022 capped monthly insulin copays at $35 for Medicare Part D enrollees beginning in January 2023, and several states have enacted their own caps for state-regulated plans. In 2023, the three dominant insulin makers — Eli Lilly, Novo Nordisk and Sanofi — voluntarily announced list-price cuts and $35 out-of-pocket caps for many patients. Bills to extend a $35 cap to all privately insured patients have been introduced in Congress but have not cleared both chambers, leaving the scope of any federal cap an open question.
Evidence
What the data show
The CDC estimates 8.4 million Americans use insulin. The 2022 RAND analysis found U.S. list prices were several times higher than in other developed countries, though net prices after rebates are lower than list prices. Studies published in JAMA Internal Medicine and elsewhere have estimated that roughly one in four insulin users has reported rationing the drug due to cost at some point. Since the Medicare cap took effect in 2023, federal data show reduced out-of-pocket spending among Part D enrollees who use insulin. The longer-term effects of the manufacturers' 2023 voluntary price cuts, and of new biosimilar competition, are still being measured by researchers and the Congressional Budget Office.
Continue exploring
Keep going.
Issue brief
Should the Electoral College Be Abolished?
Americans remain divided over whether to keep the constitutional system that has chosen presidents since 1789.
Issue brief
Did Reaganomics deliver on its promises?
Four decades on, the economic record of the Reagan era remains a contested benchmark in American policy debates.
Issue brief
Should Citizens United be overturned?
More than a decade after the Supreme Court reshaped campaign finance, Americans remain divided over whether the ruling should stand.
Issue brief
Should the federal minimum wage rise to $15 an hour?
Lawmakers and economists continue to debate whether more than doubling the $7.25 federal floor would lift workers out of poverty or cost jobs.